| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Global Blood Therapeutics missed estimated earnings by 6.78%, reporting an EPS of $-1.26 versus an estimate of $-1.18.
Revenue was up $24.00 million from the same period last year.
Last quarter the company beat on EPS by $0.04 which was followed by a 7.96% drop in the share price the next day.
Here's a look at Global Blood Therapeutics's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.30 | -1.13 | -1.11 | -1.19 |
| EPS Actual | -1.26 | -1.36 | -1.13 | -1.12 |
| Revenue Estimate | 56.14M | 55.44M | 53.70M | 43.84M |
| Revenue Actual | 55.16M | 56.10M | 52.05M | 47.55M |
To track all earnings releases for Global Blood Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GBT
